Covid-19: Sanofi and GSK to seek regulatory authorisation for protein based vaccine

Sanofi and GlaxoSmithKline’s covid-19 vaccine has 57.9% (95% confidence interval 26.5% to 76.7%) efficacy against any symptomatic disease, the companies have reported.In a phase 3 trial in which more…

Read Original Article: Covid-19: Sanofi and GSK to seek regulatory authorisation for protein based vaccine »